undamentalytics Newsletter
Sign in

Nektar Therapeutics balance sheet

At the end of fiscal 2025, Nektar Therapeutics had total assets of $280m, total liabilities of $191m and shareholders' equity of $89.8m. It held $15.1m in cash against $0 of debt: net cash of $15.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents5018152539125660519596199258835441539
Receivables—2556242016543373922610——
Inventory—71318131311111111131516191600—
Total current assets—3542773152582883504263271,4381,4221,138796546331261266739
Goodwill—777777777777777777777777770———
Total assets—5216074984354424995695092,1501,9771,5391,1177113983042801,095
Accounts payable—7339323561922101310121125
Deferred revenue (current)—21202224242114191460——————
Total current liabilities—6427679986461725682354116856851615471
Short-term debt—————0———02530——————
Long-term debt———1251251252422432452470———————
Total debt00240149161125256255253000000000
Total liabilities—431409451524405492481421433572461438344267243191192
Shareholders' equity1029119847−9036688881,7181,4051,0776803671316190903
Net debt (negative = net cash)−50−18225124122113200195248−195−96−199−25−88−35−44−15−39
Shares outstanding—95m—————————————12m20m20m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NKTR vs TNGXNKTR vs SIGAGOSS vs NKTRIVVD vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nektar Therapeutics's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nektar Therapeutics.